Information Provided By: 
Fly News Breaks for March 22, 2019
BIIB
Mar 22, 2019 | 08:43 EDT
Jefferies analyst Michael Yee lowered his price target for Biogen to $250 from $380 and maintains a Hold rating on the shares following yesterday's Alzheimer's failure. The stock, while "cheap," is not trading at an "Uber-Bear case" yet, Yee tells investors in a research note. The analyst sees downside risk to $175-$200 per share amid the "binary overhang and uncertainty" from the Tecfidera inter partes review. Further, Yee believes Spinraza consensus estimates still have to come down. He maintains a Hold rating on Biogen.
News For BIIB From the Last 2 Days
